9月9日 - ** 生物技术公司Opus Genetics（IRD.O）股价上涨55.3%，至6.75美元——创下2021年3月以来的最高水平
** 该公司表示，其用于治疗BEST1相关视网膜疾病的实验性基因疗法OPGx-BEST1（该类罕见遗传性眼疾会导致视力进行性丧失乃至失明），在一项早期至中期临床研究中，接受治疗的全部五名患者均显示出具有临床意义的视力改善
** Opus 表示，未观察到严重不良事件、剂量限制性毒性或眼部炎症
** 公司报告称，5名患者中有3名视力有所改善，4名可评估患者中有3名视网膜敏感度有所提高
** 5名患者中有4名出现结构性改善，包括与疾病相关的视网膜病变和积液减少
** Opus将高剂量组的入组人数超额扩大至8名患者；预计将于2027年第二季度公布顶线数据
** 计入本次交易后，该股今年以来累计涨幅约245%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.